Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928078 | 0.81 | FGFR1 (0.47) | DHFRFGFR1SRCTDP1CHUK | |
| SCHEMBL928124 | 0.79 | HSD17B10 (0.41) | DHFRTDP1MAPTMEN1LMNA | |
| SCHEMBL5748258 | 0.77 | FGFR1 (0.65) | FGFR1SRCLMNAEGFRCLK1 | |
| SCHEMBL5048118 | 0.76 | DAO (0.44) | DHFRTDP1CHUKMAPTLMNA | |
| SCHEMBL5046354 | 0.74 | FGFR1 (0.45) | FGFR1SRCTDP1MAPTLMNA | |
| SCHEMBL12908067 | 0.67 | ALDH1A1 (0.37) | TDP1CHUKMAPTMEN1LMNA | |
| SCHEMBL927835 | 0.67 | CHUK (0.42) | TDP1CHUKMAPTMEN1LMNA | |
| SCHEMBL3791741 | 0.66 | DHFR (0.40) | DHFRTDP1CHUKMAPTGSK3B | |
| SCHEMBL3789454 | 0.65 | DHFR (0.42) | DHFRCHUKMAPTGSK3BHASPIN | |
| SCHEMBL3790893 | 0.65 | DHFR (0.40) | DHFRTDP1CHUKNCOA1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868018-B2 | such as N [3-(2-(3-trifluoromethyl)-benzoylamino -[1,6]naphthyridin-3-yl)-2,4-dichloro-phenyl]-3-trifluoromethyl-benzamide, used as antiproliferative agents or for the treatment of autoimmune diseases and nervous system disorders | IRM LLC (BM) | 2011-01-11 | — | — | US | disclosed |
| US-7868018-B2 | such as N [3-(2-(3-trifluoromethyl)-benzoylamino -[1,6]naphthyridin-3-yl)-2,4-dichloro-phenyl]-3-trifluoromethyl-benzamide, used as antiproliferative agents or for the treatment of autoimmune diseases and nervous system disorders | IRM LLC (BM) | 2011-01-11 | — | — | US | disclosed |
| US-20080300246-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-12-04 | — | — | US | disclosed |
| US-20080300246-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-12-04 | — | — | US | disclosed |
| US-7449582-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-11-11 | — | — | US | disclosed |
| US-7449582-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-11-11 | — | — | US | disclosed |
| EP-1673343-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007021795-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-22 | — | — | WO | disclosed |
| EP-1673343-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-06-28 | — | — | EP | disclosed |
| US-20050187230-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-08-25 | — | — | US | disclosed |
| WO-2005034869-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300246-A1 | Compounds and Compositions as Protein Kinase Inhibitors | SGK2, BRSK2, FYN | DHFR 3661/4885FGFR1 239/4885SRC 4/4885 |
| US-20050187230-A1 | Compounds and compositions as protein kinase inhibitors | FYN, LCK, SRC | DHFR 2120/4885FGFR1 76/4885SRC 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.